{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:24:04Z","timestamp":1790270644257,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore the real-world efficacy and safety of telitacicept in patients with systemic lupus erythematosus (SLE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included SLE patients treated with telitacicept for at least 3 months at Mianyang Central Hospital between January 2022 and December 2025. Baseline characteristics and clinical outcomes at 12, 24, and 52 weeks were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 139 patients were enrolled in this study. The SLE Disease Activity Index 2000 (SLEDAI-2K) score significantly decreased from a baseline of 11.42 \u00b1 4.68 to 4.623 \u00b1 3.65, 2.42 \u00b1 2.98, and 1.48 \u00b1 2.58 at 12, 24, and 52 weeks, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.0001). The anti-dsDNA positivity rate declined from 35.25% at baseline to 7.94% by week 52, accompanied by an upward trend in complement 3 (C3) and complement 4 (C4) levels. Among the 74 patients with lupus nephritis, the baseline 24-hour urine protein was 1.59 \u00b1 1.68 g\/24h, which significantly decreased to 1.12 \u00b1 1.41 g\/24h, 0.42 \u00b1 0.46 g\/24h, and 0.39 \u00b1 0.64 g\/24h at 12 weeks, 24 weeks, and 52 weeks, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). The serum albumin level significantly increased (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.0001), while the serum estimated glomerular filtration rate (eGFR) showed significant reductions (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.05). Furthermore, white blood cell and platelet count also improved significantly in patients with leukopenia and thrombocytopenia (P &amp;lt; 0.0001). The mean daily glucocorticoids dose (equivalent to prednisone) was successfully tapered from 39.98 \u00b1 10.09 mg\/d at baseline to 18.35 \u00b1 7.87 mg\/d at 12 weeks, 9.752 \u00b1 4.72 mg\/d at 24 weeks, and 5.69 \u00b1 2.95 mg\/d at 52 weeks (\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.0001). Adverse events occurred in 28 (20.14%) patients, with upper respiratory tract infections being the most common (53%), and no serious adverse events occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world study, telitacicept combined with conventional therapy was associated with improvements in disease activity and organ functions in SLE with favorable safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1890148","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:35:07Z","timestamp":1785216907000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of telitacicept in systemic lupus erythematosus: a single-center, retrospective, real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Li","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Mian Yang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Mian Yang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmei","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Mian Yang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Mian Yang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","unstructured":"Systemic lupus erythematosus\n          \n          \n            \n              Justiz Vaillant\n              AA\n            \n            \n              Goyal\n              A\n            \n            \n              Varacallo\n              MA\n            \n          \n          Treasure Island (FL\n          Statpearls Publishing\n          Statpearls\n          \n          2026"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex260","article-title":"The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies","volume":"56","author":"Rees","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1426.2020.03.002","article-title":"2020 chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus","volume":"59","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/art.40396","article-title":"Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us","volume":"70","author":"Karrar","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30330","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1155421","article-title":"B cell activation via immunometabolism in systemic lupus erythematosus","volume":"14","author":"Iwata","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0446-6","article-title":"-Omics\u201d shed light on B cells in lupus","volume":"20","author":"Pernis","year":"2019","journal-title":"Nat Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheumatic Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169084","article-title":"Telitacicept for autoimmune nephropathy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.01.001","article-title":"Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers","volume":"125","author":"D\u00f6rner","year":"2010","journal-title":"Pharmacol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13075-017-1451-5","article-title":"Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus","volume":"19","author":"Piga","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000616","article-title":"LLDAS (lupus low disease activity state) and\/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort","volume":"9","author":"Ugarte-Gil","year":"2022","journal-title":"Lupus Sci Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05940-z","article-title":"Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort","volume":"41","author":"Hao","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224919","article-title":"Pragmatic targets for moderate\/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression","volume":"83","author":"Pitsigavdaki","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2478\/rir-2022-0006","article-title":"The challenges and future perspective for the management of systemic lupus erythematosus in China: a concise annual report of 2020","volume":"3","author":"Tian","year":"2022","journal-title":"Rheumatol Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.489","article-title":"Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB\/W F1 mice by a mechanism downstream of renal immune complex deposition","volume":"171","author":"Schiffer","year":"2003","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.279.5353.1052","article-title":"Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis","volume":"279","author":"Clynes","year":"1998","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.immuni.2018.03.027","article-title":"T follicular helper cell-germinal center B cell interaction strength regulates entry into plasma cell or recycling germinal center cell fate","volume":"48","author":"Ise","year":"2018","journal-title":"Immunity"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20170580","article-title":"B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity","volume":"214","author":"Arkatkar","year":"2017","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114596","article-title":"Efficacy and safety of telitacicept in patients with class III-V lupus nephritis: a real-world retrospective cohort study","volume":"154","author":"Chen","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-024-02501-x","article-title":"Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study","volume":"28","author":"Huang","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1473190","article-title":"Successful treatment of refractory systemic lupus erythematosus-associated immune thrombocytopenia with drug-induced liver injury with telitacicept: a case report and review","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1890148\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:35:11Z","timestamp":1785216911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1890148\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1890148"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1890148","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1890148"}}